[Featured Stock] Prostemics Commercializes COVID-19 Cytokine Storm Suppression Technology... Plans IND for Inflammatory Bowel Disease New Drug

[Asia Economy Reporter Hyunseok Yoo] Prostemics is showing strong performance.

As of 11:22 AM on the 15th, Prostemics recorded 4,060 KRW, up 14.53% (515 KRW) compared to the previous trading day.

Prostemics recently announced a new product containing kefir grain-derived probiotic exosomes amid growing interest in immunity due to the novel coronavirus infection (COVID-19), stating its intention to lead the microbiome market.

Based on advanced and latest exosome production technology, the company is building pipelines not only for treatments of Inflammatory Bowel Disease (IBD) but also microbiome-based anticancer therapies and atopic dermatitis treatments. It is strengthening new drug development as a new business.

A company official said, "We have confirmed excellent immune regulatory functions and anti-inflammatory treatment efficacy, such as suppressing cytokine storm (hyperimmune response) expression in probiotic exosomes," adding, "We plan to apply for an Investigational New Drug (IND) clinical trial for the treatment of Inflammatory Bowel Disease."

Founded in 2005, Prostemics is the world's first first-generation company to register exosomes as raw materials with the Personal Care Products Council (PCPC) in the United States, specializing in stem cell culture technology. Through its proprietary stem cell culture medium commercialization platform, 'Exoplant®', it possesses production capabilities and technology to culture, isolate, purify, and mass-produce high-quality exosomes.

This content was produced with the assistance of AI translation services.